HC Wainwright Estimates Aethlon Medical FY2031 Earnings

Aethlon Medical, Inc. (NASDAQ:AEMD) – Equities researchers at HC Wainwright issued their FY2031 EPS estimates for Aethlon Medical in a research note issued on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth forecasts that the medical equipment provider will post earnings of $0.07 per share for the year. HC Wainwright currently has a “Neutral” rating and a $1.50 target price on the stock. The consensus estimate for Aethlon Medical’s current full-year earnings is ($16.15) per share.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) EPS for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10).

AEMD has been the subject of several other reports. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $1.50.

Aethlon Medical Price Performance

Shares of AEMD stock opened at $2.89 on Wednesday. The stock has a market capitalization of $1.88 million, a PE ratio of -0.08 and a beta of 1.41. The business’s 50 day simple moving average is $4.55 and its 200 day simple moving average is $8.58. Aethlon Medical has a one year low of $2.63 and a one year high of $137.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical at the end of the most recent quarter. Institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.